Computational Design and Glycoengineering of Interferon-Lambda for Nasal Prophylaxis Against Respiratory Viruses.

Additionally, administering 1 μg intranasal dose 24 h before viral challenge (24 h pre‐dose → infection → 48 h readout) minimized the apparent prophylactic differences among variants (Figure 6f ), while G‐hIFN‐λ3‐DE1 showed a trend toward greater reduction, likely due to the saturation of interferon‐stimulated pathways.

also in 53,322 other papers